Insys Therapeutics announced that it has signed a definitive license agreement with Lunatus for commercialization of Subsys in eight countries in the Middle East. In May, the two companies announced their intent to form an exclusive partnership. This announcement confirms that the definitive agreement has been executed, making Dubai-based Lunatus the exclusive licensee and authorized agent for Subsys in the territory, which comprises Bahrain, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia and the United Arab Emirates.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.